Amjad Hussain 1 , Maham Misbah 1 , Nasir Abbas 1 , Muhammad Irfan 2 , Muhammad Sohail Arshad 3 , Rahat Shamim 1 , Nadeem Irfan Bukhari 1 , Faisal Mahmood 1 Show Affiliations »
Abstract
OBJECTIVES: The aim of this study was to prepare orally disintegrating, slow release tablets of naproxen sodium for prompt onset and sustained action required in many types of acute pain. MATERIALS AND METHODS: Tablet formulations containing varying concentrations of croscarmellose sodium (a superdisintegrant) and Soluplus® (as release modifier) were prepared by wet granulation method using a single punch tablet machine. The prepared granules were evaluated for their bulk properties and the tablets were evaluated for hardness, disintegration time, and drug release profiles. RESULTS: The results showed that the granules so prepared have good flow and compressional properties. A disintegration time of tablets <30 s was achieved by selecting an optimum concentration of croscarmellose sodium. The drug release from the tablets was sustained for 2 h by incorporating a suitable amount of Soluplus®. CONCLUSION: This study examined the use of Soluplus® (a novel solubilizer) for the first time as a release modifier of API from tablets. ©Copyright 2020 Turk J Pharm Sci, Published by Galenos Publishing House.
OBJECTIVES: The aim of this study was to prepare orally disintegrating, slow release tablets of naproxen sodium for prompt onset and sustained action required in many types of acute pain. MATERIALS AND METHODS: Tablet formulations containing varying concentrations of croscarmellose sodium (a superdisintegrant) and Soluplus® (as release modifier) were prepared by wet granulation method using a single punch tablet machine. The prepared granules were evaluated for their bulk properties and the tablets were evaluated for hardness, disintegration time, and drug release profiles. RESULTS: The results showed that the granules so prepared have good flow and compressional properties. A disintegration time of tablets <30 s was achieved by selecting an optimum concentration of croscarmellose sodium. The drug release from the tablets was sustained for 2 h by incorporating a suitable amount of Soluplus®. CONCLUSION: This study examined the use of Soluplus® (a novel solubilizer) for the first time as a release modifier of API from tablets. ©Copyright 2020 Turk J Pharm Sci, Published by Galenos Publishing House.
Entities: Chemical
Keywords:
Orally disintegrating tablets; Soluplus®; modified release tablets; naproxen sodium
Year: 2020
PMID： 33177928 PMCID： PMC7650740 DOI： 10.4274/tjps.galenos.2019.24445
Source DB: PubMed Journal: Turk J Pharm Sci ISSN： 1304-530X